These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 17913341

  • 1. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A, Mantovani G, Spada A.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):180-6. PubMed ID: 17913341
    [Abstract] [Full Text] [Related]

  • 2. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A, Jaquet P, Brue T, Barlier A.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):206-13. PubMed ID: 18241980
    [Abstract] [Full Text] [Related]

  • 3. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P.
    Neuroendocrinology; 2006 May 14; 83(3-4):258-63. PubMed ID: 17047391
    [Abstract] [Full Text] [Related]

  • 4. New SRIF analogs in the control of human pituitary adenomas: perspectives.
    Jaquet P, Saveanu A, Barlier A.
    J Endocrinol Invest; 2005 May 14; 28(5 Suppl):14-8. PubMed ID: 16114269
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S.
    Endocr J; 2004 Apr 14; 51(2):227-36. PubMed ID: 15118275
    [Abstract] [Full Text] [Related]

  • 6. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP.
    J Endocrinol; 2016 Nov 14; 231(2):135-145. PubMed ID: 27587848
    [Abstract] [Full Text] [Related]

  • 7. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW.
    J Endocrinol Invest; 2005 Nov 14; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [Abstract] [Full Text] [Related]

  • 8. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M, Lawnicka H, Pisarek H, Kunert-Radek J, Radek M, Culler MD.
    J Physiol Pharmacol; 2007 Mar 14; 58(1):179-88. PubMed ID: 17440235
    [Abstract] [Full Text] [Related]

  • 9. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
    Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR.
    J Clin Endocrinol Metab; 2009 Jun 14; 94(6):1931-7. PubMed ID: 19293270
    [Abstract] [Full Text] [Related]

  • 10. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
    Durán-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P, Dufour H, Malagón MM, Culler MD, Barlier A, Castaño JP.
    J Clin Endocrinol Metab; 2010 May 14; 95(5):2497-502. PubMed ID: 20233783
    [Abstract] [Full Text] [Related]

  • 11. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment.
    Ballarè E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A.
    J Clin Endocrinol Metab; 2001 Aug 14; 86(8):3809-14. PubMed ID: 11502816
    [Abstract] [Full Text] [Related]

  • 12. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
    Gatto F, Feelders RA, Franck SE, van Koetsveld PM, Dogan F, Kros JM, Neggers SJCMM, van der Lely AJ, Lamberts SWJ, Ferone D, Hofland LJ.
    J Clin Endocrinol Metab; 2017 Jun 01; 102(6):2009-2018. PubMed ID: 28323931
    [Abstract] [Full Text] [Related]

  • 13. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.
    Acunzo J, Thirion S, Roche C, Saveanu A, Gunz G, Germanetti AL, Couderc B, Cohen R, Figarella-Branger D, Dufour H, Brue T, Enjalbert A, Barlier A.
    Cancer Res; 2008 Dec 15; 68(24):10163-70. PubMed ID: 19074883
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
    Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez-Borrego MC, Bitana L, Camacho AHDS, Silva D, Ogino LL, Ventura N, Sánchez-Sánchez R, Chimelli L, Kasuki L, Luque RM, Gadelha MR.
    Sci Rep; 2019 Feb 04; 9(1):1122. PubMed ID: 30718563
    [Abstract] [Full Text] [Related]

  • 15. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD, degli Uberti EC.
    J Mol Endocrinol; 2005 Oct 04; 35(2):333-41. PubMed ID: 16216913
    [Abstract] [Full Text] [Related]

  • 16. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
    Marina D, Burman P, Klose M, Casar-Borota O, Luque RM, Castaño JP, Feldt-Rasmussen U.
    Growth Horm IGF Res; 2015 Oct 04; 25(5):262-7. PubMed ID: 26188991
    [Abstract] [Full Text] [Related]

  • 17. [New medical treatments in pituitary adenomas].
    Drutel A, Caron P, Archambeaud F.
    Ann Endocrinol (Paris); 2008 Sep 04; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [Abstract] [Full Text] [Related]

  • 18. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
    Gatto F, Arvigo M, Ferone D.
    J Endocrinol Invest; 2020 Nov 04; 43(11):1543-1553. PubMed ID: 32557353
    [Abstract] [Full Text] [Related]

  • 19. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas.
    Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S.
    J Clin Endocrinol Metab; 2008 Apr 04; 93(4):1203-10. PubMed ID: 18198230
    [Abstract] [Full Text] [Related]

  • 20. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L.
    Neuroendocrinology; 2004 Mar 04; 79(3):142-8. PubMed ID: 15103227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.